Detailed Narrative
Q3 & 9M FY26 Financial Performance Overview
Indogulf Cropsciences reported a strong Q3 FY26, with revenue from operations increasing by 17% year-on-year to ₹116.1 crores. EBITDA grew by 16% to ₹11.7 crores, and Profit Before Tax (PBT) rose from ₹4.6 crores in Q3 FY25 to ₹7.4 crores. For the nine months ended December 31, 2025 (9M FY26), revenue from operations reached ₹553 crores, marking a robust 19.3% year-on-year growth. EBITDA for 9M FY26 increased by 23% to ₹53.6 crores, and PBT was up 33.2% to ₹39.1 crores, reflecting improved operating leverage and product mix.
Segmental and Regional Growth Drivers
In 9M FY26, all three verticals demonstrated healthy growth: Biologicals grew by 15%, Plant Nutrition by 23%, and Crop Protection by 14%. The combined revenue from Biologicals and Plant Nutrition increased to ₹56 crores from ₹47 crores in the prior year. Both B2C and B2B segments showed strong performance, with B2C growing 16% to ₹301.6 crores and B2B growing 26% to ₹219.4 crores. Regionally, Tamil Nadu led with 80% growth, followed by Haryana (66%), Bihar (58%), Uttar Pradesh (31%), and Himachal (22%).
AGPL's Contribution and Future Expansion
Abhiprakash Globus Private Limited (AGPL) made a significant contribution in its first full year of operations, achieving gross sales of ₹54 crores in 9M FY26. AGPL's performance was bolstered by operational efficiencies, channel alignment, and a better product mix, supporting margin expansion. The company plans to expand AGPL's footprint into additional states, particularly in central India, to strengthen its geographic presence and widen its customer base.
Strategic Initiatives and Market Outlook
Indogulf has consciously normalized its inventory levels, positioning itself to benefit from improving demand trends. The company anticipates good potential for demand in Q4 FY26 and Q1 FY27, supported by a healthier supply chain and improved market sentiment. Regulatory tailwinds, such as the Draft Pesticide Management Bill 2025 and the proposed Seed Bill 2025, are expected to benefit organized players by prioritizing quality control and digital traceability.
International Market Expansion
The company made steady progress on its international growth agenda, successfully entering new markets like Venezuela, Taiwan, and Sudan during the quarter. Initial orders totaling approximately ₹4-5 crores have been received from these countries and are expected to be executed in Q4 FY26. These new market entries are part of a strategy to build a broader global footprint, diversify revenue streams, and leverage the product portfolio in high-potential international markets.
Capacity Expansion Update
The commissioning of the new facility at Barwasni has been delayed by 2-3 months due to the GRAP (Graded Response Action Plan) situation in Delhi NCR. The company now expects the new facility to be operational by the end of Q1 FY27. This expansion is anticipated to reflect positively in future performance and support growth across all three sectors.
Product Strategy and Volume Growth
Management indicated that the revenue growth achieved was primarily quantitative, with minimal price impact. Quantitative incremental growth was estimated to be 1% to 2% higher than value-wise growth due to a slight average drop in prices. The company plans to launch four to five new products in Q1 FY27, as product launches are typically concentrated in the first two quarters of the year to align with state-wise campaigns.